These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 12108946)
1. The promise and obstacle of p53 as a cancer therapeutic agent. Willis AC; Chen X Curr Mol Med; 2002 Jun; 2(4):329-45. PubMed ID: 12108946 [TBL] [Abstract][Full Text] [Related]
3. Restoration of wild-type p53 function in human cancer: relevance for tumor therapy. Bossi G; Sacchi A Head Neck; 2007 Mar; 29(3):272-84. PubMed ID: 17230559 [TBL] [Abstract][Full Text] [Related]
5. Induction of genetic instability by gain-of-function p53 cancer mutants. Xu Y Oncogene; 2008 Jun; 27(25):3501-7. PubMed ID: 18223686 [TBL] [Abstract][Full Text] [Related]
6. Advances in adenovirus-mediated p53 cancer gene therapy. Tazawa H; Kagawa S; Fujiwara T Expert Opin Biol Ther; 2013 Nov; 13(11):1569-83. PubMed ID: 24107178 [TBL] [Abstract][Full Text] [Related]
7. New p53-based anti-cancer therapeutic strategies. Wiman KG Med Oncol; 1998 Dec; 15(4):222-8. PubMed ID: 9951684 [TBL] [Abstract][Full Text] [Related]
8. Targeting mutant p53 for cancer therapy: direct and indirect strategies. Hu J; Cao J; Topatana W; Juengpanich S; Li S; Zhang B; Shen J; Cai L; Cai X; Chen M J Hematol Oncol; 2021 Sep; 14(1):157. PubMed ID: 34583722 [TBL] [Abstract][Full Text] [Related]
9. Targeting p53 in cancer. Chène P Curr Med Chem Anticancer Agents; 2001 Aug; 1(2):151-61. PubMed ID: 12678764 [TBL] [Abstract][Full Text] [Related]
10. Wild type p53 function in p53 Sundar D; Yu Y; Katiyar SP; Putri JF; Dhanjal JK; Wang J; Sari AN; Kolettas E; Kaul SC; Wadhwa R J Exp Clin Cancer Res; 2019 Feb; 38(1):103. PubMed ID: 30808373 [TBL] [Abstract][Full Text] [Related]
11. Restoration of wild-type p53 function in human tumors: strategies for efficient cancer therapy. Wiman KG Adv Cancer Res; 2007; 97():321-38. PubMed ID: 17419952 [TBL] [Abstract][Full Text] [Related]
12. Adenovirus-mediated p53 gene therapy in pediatric soft-tissue sarcoma cell lines: sensitization to cisplatin and doxorubicin. Ganjavi H; Gee M; Narendran A; Freedman MH; Malkin D Cancer Gene Ther; 2005 Apr; 12(4):397-406. PubMed ID: 15618970 [TBL] [Abstract][Full Text] [Related]
13. Targeting tumor suppressor p53 for cancer therapy: strategies, challenges and opportunities. Hong B; van den Heuvel AP; Prabhu VV; Zhang S; El-Deiry WS Curr Drug Targets; 2014 Jan; 15(1):80-9. PubMed ID: 24387333 [TBL] [Abstract][Full Text] [Related]
14. Therapeutic targeting of the p53 tumor suppressor gene. Beaudry GA; Bertelsen AH; Sherman MI Curr Opin Biotechnol; 1996 Dec; 7(6):592-600. PubMed ID: 8939636 [TBL] [Abstract][Full Text] [Related]
16. Novel cancer therapy by reactivation of the p53 apoptosis pathway. Bykov VJ; Wiman KG Ann Med; 2003; 35(7):458-65. PubMed ID: 14649328 [TBL] [Abstract][Full Text] [Related]
17. p53 as a therapeutic target. Staples OD; Steele RJ; Lain S Surgeon; 2008 Aug; 6(4):240-3. PubMed ID: 18697367 [TBL] [Abstract][Full Text] [Related]
18. Cancer-specific gene therapy. Lo HW; Day CP; Hung MC Adv Genet; 2005; 54():235-55. PubMed ID: 16096014 [TBL] [Abstract][Full Text] [Related]
19. Small molecules that reactivate mutant p53. Bykov VJ; Selivanova G; Wiman KG Eur J Cancer; 2003 Sep; 39(13):1828-34. PubMed ID: 12932659 [TBL] [Abstract][Full Text] [Related]
20. Ribozyme-mediated induction of apoptosis in human cancer cells by targeted repair of mutant p53 RNA. Shin KS; Sullenger BA; Lee SW Mol Ther; 2004 Aug; 10(2):365-72. PubMed ID: 15294183 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]